You are here: Industry Insights > COV002

News List

Vaxzevria Induced Immunity for at Least One Year Following a Single Dose and Strong Immune Responses Following Either a Late Second Dose or a Third Dose drugs
July 08, 2021
A sub-analysis from the Oxford-led COV001 and COV002 trials with Vaxzevria induced strong immune responses following either a prolonged second dose interval of up to 45 weeks or following a third boosting dose.
A Single Dose of Vaxzevria Induced Immunity for One Year, Second and Third Dose Increase Response americanpharmaceuticalreview
June 30, 2021
Oxford-led COV001 and COV002 trials showed that Vaxzevria induced a strong immune response following a long second dose interval (up to 45 weeks) and after a third booster dose.
AstraZeneca COVID-19 Vaccine Confirms 100% Protection Against Severe Disease in Phase III Trials americanpharmaceuticalreview
February 08, 2021
The primary analysis of the Phase III clinical trials from the UK, Brazil and South Africa, published as a preprint in The Lancet confirmed COVID-19 Vaccine AstraZeneca is safe and effective at preventing COVID-19, with no severe cases and no ...